
Journal of Materials Chemistry B



CORRECTION

View Article Online



Cite this: J. Mater. Chem. B, 2024, 12, 275

Correction: Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway

Qian Bai, ^a Yaoyao Zhou, ^a Xiaona Cui, ^{ab} Haichao Si, ^e Tingting Wu, ^a Abdul Nasir, ^{ac} Heng Ma, ac Junyue Xing, Yingying Wang, Xiaolei Cheng, Xiaojun Liu, *b Shaoyan Qi,*b Zhisong Lic and Hao Tang*d

DOI: 10.1039/d3tb90183a

rsc.li/materials-b

Correction for 'Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway' by Qian Bai et al., J. Mater. Chem. B, 2023, https://doi.org/10.1039/ d3tb00929q

The authors regret the error in Fig. 6 due to a figure compilation error. The corrected Fig. 6 is shown below.

^a Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China

b Department of Critical Care Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. E-mail: liuxiaojunzzu@163.com,

^c Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

d National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Fuwai Central China Cardiovascular Hospital & Central China Branch of National Center for Cardiovascular Diseases, Zhengzhou, Henan, 451464, China, E-mail: tangpku zzuhao@zzu.edu.cn

^e Department of Anesthesiology, Nanyang Central Hospital, Nanyang, Henan, China




Fig. 6 Intravenous Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated the TNFα/NF-κB/Neat1 pathways in a mouse TMD pain model. (A) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated Neat1 in Sp5C in mouse TMD pain model after 3 d; **P < 0.01; ****P < 0.01; ******* < 0.01; ******* < 0.01; ******** < 0.01; ******** < 0.01; ******** < 0.01; ******** < 0.01; ********* < 0.01; ********* < 0.01; ********* < 0.01; ********* < 0.01; ********* < 0.01; ********* < 0.01; ******** < 0.01; ******** < 0.01; ******** < 0.01; ******** < 0.01; ******** < 0.01; ******* < 0.01; ******* < 0.01; ******* < 0.01; ******* < 0.01; ****** < 0.01; ****** < 0.01; ****** < 0.01; ****** < 0.01; ****** < 0.01; ****** < 0.01; ***** < 0.01; ***** < 0.01; ***** < 0.01; ***** < 0.01; ***** < 0.01; ***** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; **** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.01; *** < 0.0001, two-way ANOVA, N = 18. (B) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection downregulated p-p65 in Sp5C in mouse TMD pain model after 3 d; ****P < 0.0001 vs. CFA + vehicle; two-way ANOVA, N = 39. (C) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA/saline injection did not alter p65 expression in Sp5C after 3 d; nsp > 0.05, N = 27. (D) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection counteracted the increase in p-p65 immunofluorescence intensity in Sp5C in mouse TMD pain model after 3 d (scale bar = 400 µm). (E) Statistical analysis of data in (D) ****P < 0.0001 vs. CFA + vehicle group, N = 3, two-way ANOVA. (F) Intra-Sp5C NF- κ B injection in downregulated Neat1 in naive mice; **P < 0.01 vs. Scramble control, N = 5; t-test. (G) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated TNF- α in Sp5C in mouse TMD pain model after 3 d; ***P < 0.001 vs. CFA + vehicle, N = 4; two-way ANOVA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.